Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGDR2 | Q9Y5Y4 | 19/20 | 0.60 |
| ▸ | AKR1B1 | P15121 | 4/20 | 0.55 |
| ▸ | AKR1B10 | O60218 | 1/20 | 0.47 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.44 |
| ▸ | PTGDR | Q13258 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1785003 | 0.95 | PTGDR2 (0.56) | PTGDR2AKR1B1AKR1B10CYP2C9PTGDR | |
| SCHEMBL1787716 | 0.93 | PTGDR2 (0.64) | PTGDR2AKR1B1CYP2C9PTGDR | |
| SCHEMBL1785965 | 0.87 | PTGDR2 (0.56) | PTGDR2AKR1B1CYP2C9PTGDR | |
| SCHEMBL5749195 | 0.83 | PTGDR2 (0.43) | PTGDR2AKR1B1AKR1B10CYP2C9PTGDR | |
| SCHEMBL2088388 | 0.81 | PTGDR2 (0.52) | PTGDR2AKR1B1CYP2C9PTGDR | |
| SCHEMBL1788163 | 0.81 | PTGDR2 (0.66) | PTGDR2AKR1B1CYP2C9PTGDR | |
| SCHEMBL5739375 | 0.79 | PTGDR2 (0.55) | PTGDR2AKR1B1CYP2C9PTGDR | |
| Demeton S SCHEMBL2917009 | 0.79 | PTGDR2 (0.51) | PTGDR2AKR1B1CYP2C9PTGDR | |
| SCHEMBL1786162 | 0.78 | PTGDR2 (0.62) | PTGDR2CYP2C9PTGDR | |
| SCHEMBL1467977 | 0.77 | PTGDR2 (0.62) | PTGDR2AKR1B1CYP2C9PTGDR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1682121-A1 | USE OF CRTH2 ANTAGONIST COMPOUNDS IN THERAPY | Oxagen Limited (GB) | 2006-07-26 | — | — | EP | claimed |
| WO-2005044260-A1 | USE OF CRTH2 ANTAGONIST COMPOUNDS IN THERAPY | OXAGEN LIMITED (GB) | 2005-05-19 | — | — | WO | claimed |
| EP-2790696-A1 | COMBINATION OF CRTH2 ANTAGONIST AND A PROTON PUMP INHIBITOR FOR THE TREATMENT OF EOSINOPHILIC ESOPHAGITIS | Atopix Therapeutics Limited (GB) | 2014-10-22 | — | — | EP | disclosed |
| WO-2013088109-A1 | COMBINATION OF CRTH2 ANTAGONIST AND A PROTON PUMP INHIBITOR FOR THE TREATMENT OF EOSINOPHILIC ESOPHAGITIS | OXAGEN LIMITED (GB) | 2013-06-20 | — | — | WO | disclosed |